New hope for liver cancer patients with cirrhosis? tiny trial tests drug duo
NCT ID NCT04829383
First seen Jun 25, 2026 · Last updated Jun 27, 2026 · Updated 1 time
Summary
This small, completed phase II study tested the safety of combining two drugs—atezolizumab (an immunotherapy) and bevacizumab (a blood vessel blocker)—in 6 people with advanced liver cancer who also had moderate cirrhosis (Child-Pugh B7 or B8). The goal was to see if this treatment could be safely given to patients who are often excluded from other trials. The study focused on tracking serious side effects and tumor response.
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
Active substance
atezolizumab (Tecentriq) and bevacizumab (Avastin)
What this could lead to
If successful, this could show that the drug combination is safe enough to use in patients with more advanced liver disease, potentially expanding treatment options for this hard-to-treat group.
What could go wrong
This is a very small, early-phase feasibility study with only 6 participants, so results may not apply broadly. The drugs also carry risks of serious side effects, especially in patients with already-compromised liver function.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for UNRESECTABLE HEPATOCELLULAR CARCINOMA are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Locations
-
DHR Health Institute for Research and Development
Edinburg, Texas, 785329, United States
-
Indiana University Melvin and Bren Simon Comprehensive Cancer Center
Indianapolis, Indiana, 46202, United States
-
New York University Clinical Cancer Center
New York, New York, 10016, United States
-
Rutgers Cancer Institute of New Jersey
New Brunswick, New Jersey, 08903, United States
-
Univeristy of Wisconsin
Madison, Wisconsin, 53705, United States
-
University of Illinois Cancer Center
Chicago, Illinois, 60612, United States
-
University of Nebraska Medical Center
Omaha, Nebraska, 68198, United States